Identification and validation of an immunogenic subtype of gastric cancer with abundant intratumoural CD103+CD8+ T cells conferring favourable prognosis
-
Published:2020-03-24
Issue:10
Volume:122
Page:1525-1534
-
ISSN:0007-0920
-
Container-title:British Journal of Cancer
-
language:en
-
Short-container-title:Br J Cancer
Author:
Li Ruochen,Liu Hao,Cao Yifan,Wang Jieti,Chen Yifan,Qi Yangyang,Lv Kunpeng,Liu Xin,Yu Kuan,Lin Chao,Zhang Heng,He Hongyong,Li He,Chen Lingli,Shen Zhenbin,Qin Jing,Zhang Weijuan,Sun Yihong,Xu Jiejie
Abstract
Abstract
Background
Intratumoural CD103+CD8+ T cells have been linked to prolonged survival in several malignancies. However, the clinical significance of CD103+CD8+ T cells in gastric cancer remains unexplored.
Methods
Gastric cancer tissues from Zhongshan Hospital and data from Gene Expression Omnibus were obtained and analysed. Immunohistochemistry and flow cytometry were performed to detect the number and phenotypical characteristics of CD103+CD8+ T cells. The effect of programmed cell death protein-1 (PD-1) blockade on CD103+CD8+ T cells was evaluated with the use of an in vitro study based on fresh tumour tissues.
Results
CD103+CD8+ T cells predicted superior overall survival and provided better prognostic power than total CD8+ T cells in gastric cancer. Patients with high CD103+CD8+ T cell infiltration also gained more benefit from adjuvant chemotherapy. Flow cytometry analysis showed that CD103+CD8+ T cells exerted superior anti-tumour effects with stronger retention capacity and cytotoxicity. Moreover, an in vitro study showed that CD103+CD8+ T cells were more functionally restored after PD-1 blockade than CD103-CD8+ T cells.
Conclusions
CD103+CD8+ T cells might be a useful marker to predict prognosis and therapeutic efficacy for gastric cancer patients. Efforts to increase intratumoural CD103+CD8+ T cell frequency might be a novel therapeutic strategy in gastric cancer.
Publisher
Springer Science and Business Media LLC
Subject
Cancer Research,Oncology
Reference45 articles.
1. Van Cutsem, E., Sagaert, X., Topal, B., Haustermans, K. & Prenen, H. Gastric cancer. Lancet (Lond., Engl.) 388, 2654–2664 (2016). 2. Cheong, J. H., Yang, H. K., Kim, H., Kim, W. H., Kim, Y. W., Kook, M. C. et al. Predictive test for chemotherapy response in resectable gastric cancer: a multi-cohort, retrospective analysis. Lancet Oncol. 19, 629–638 (2018). 3. Wang, F., Meng, W., Wang, B. & Qiao, L. Helicobacter pylori-induced gastric inflammation and gastric cancer. Cancer Lett. 345, 196–202 (2014). 4. Yolanda, L. V., Sergio, P. D., Hugo, E. S., Isabel, A. F., Rafael, B. Z., Aldo, T. D. et al. Gastric cancer progression associated with local humoral immune responses. BMC Cancer 15, 924 (2015). 5. Tsujimoto, H., Ono, S., Ichikura, T., Matsumoto, Y., Yamamoto, J. & Hase, K. Roles of inflammatory cytokines in the progression of gastric cancer: friends or foes? Gastric Cancer. Off. J. Int. Gastric Cancer. Assoc. Jpn. Gastric Cancer. Assoc. 13, 212–221 (2010).
Cited by
35 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
|
|